文献速递心境障碍

英国新诊断双相障碍患者精神科处方模式:2000至2022年

Psychiatric prescribing patterns in patients with newly diagnosed bipolar disorder in the UK: 2000 to 2022.
PubMed 文献 · Br J Psychiatry · 2026-07-17

结果显示诊断后抗抑郁药单药治疗仍占28.9%,锂盐仅18.5%使用,处方模式高度变异且常偏离指南推荐。

要点

  • 诊断前最常见治疗为抗抑郁药单药(48.4%),诊断后仍达28.9%。
  • 诊断后最常见治疗为抗精神病药单药(36.0%),锂盐仅18.5%使用。
  • 男性、少数族裔及最贫困地区患者接受锂盐或抗抑郁药单药治疗的几率更低。

核心结论

  • 英国双相障碍处方模式高度变异,常偏离指南推荐,表现为抗抑郁药单药持续使用和锂盐潜在利用不足。

主要发现

  • 诊断前79.2%患者接受相关药物治疗,诊断后升至90.8%。
  • 诊断前抗抑郁药单药治疗占48.4%,诊断后至少1个月内仍占28.9%。
  • 诊断后抗精神病药单药治疗最常见,占36.0%。
  • 诊断1年内锂盐处方率为18.5%,其中4.0%作为一线单药治疗。
  • 46.0%患者在诊断1年内至少更换一次药物。

关键数值与推荐

  • 锂盐为双相障碍一线治疗,抗抑郁药单药可能诱发某些患者躁狂症状。

临床怎么用

  • 临床应警惕新诊断双相障碍患者持续使用抗抑郁药单药,并评估锂盐使用不足的问题。
  • 关注男性、少数族裔及最贫困地区患者接受锂盐或抗抑郁药单药治疗几率较低的现象。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Bipolar disorder is an episodic mental illness, often requiring complex pharmacological management. Lithium is a first-line treatment, while antidepressant monotherapy can precipitate mania symptoms in some patients. AIMS: To (a) describe patterns of antidepressant, antipsychotic and mood stabiliser prescribing in the 12-month periods before and after first-recorded bipolar diagnosis; (b) describe treatment trajectories in the year post-diagnosis; and (c) investigate associations between sociodemographic and treatment-related characteristics of (i) antidepressant monotherapy and (ii) lithium prescription post-diagnosis. METHOD: A longitudinal cohort study of patients with a first-recorded diagnosis of bipolar disorder between 2000 and 2022 derived from Clinical Practice Research Datalink. Prescriptions for antidepressants, antipsychotics and mood stabilisers were examined in the 12 months before and after diagnosis. Logistic regression models tested associations between sociodemographic and treatment-related characteristics and prescribing outcomes. A web application (https://dop-mhds.shinyapps.io/bpd-prescribing-uk-shiny/) was developed to visualise treatment trajectories over the year following diagnosis. RESULTS: We included 40 965 patients with a first-recorded diagnosis of bipolar disorder between 2000 and 2022 (median age at diagnosis 43 years, 60.9% female, 11.1% ethnic minority). Of these, 32 460 (79.2%) were prescribed a relevant medication in the year prior to diagnosis compared with 37 208 (90.8%) in the year after. Antidepressant monotherapy was the most common pre-diagnosis treatment (48.4%), but was also prescribed to 28.9% during at least 1 month in the year after diagnosis. Antipsychotic monotherapy was the most common post-diagnosis treatment (36.0%). Lithium was prescribed to 18.5% within 1 year of diagnosis, with 4.0% receiving it as first-line monotherapy. Almost half (46.0%) switched medication at least once within 1 year. Males, ethnic minorities and patients residing in the most deprived areas had lower odds of receiving either lithium or antidepressant monotherapy. CONCLUSIONS: Prescribing patterns for bipolar disorder in the UK are highly variable and often outside of guideline recommendations, with persistent use of antidepressant monotherapy and potential under-utilisation of lithium.

来源:Br J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Barnett JF, Wu SM, Launders N, et al. Psychiatric prescribing patterns in patients with newly diagnosed bipolar disorder in the UK: 2000 to 2022. Br J Psychiatry. 2026. PMID: 42464904. doi:10.1192/bjp.2026.10709

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。